Reapplix

Reapplix is a Danish medtech company founded in 2008 that focuses on the biological treatment of diabetic foot ulcers. Its main product, the 3C Patch® System (also known as LeucoPatch®), is an innovative wound therapy made entirely from the patient's own blood components. This autologous patch is designed to stimulate healing in chronic diabetic foot ulcers by utilizing the body's natural healing abilities. The technology has been validated through clinical research, including a randomized controlled trial published in *The Lancet Diabetes & Endocrinology*, which showed improved healing outcomes compared to standard care. Reapplix has received FDA approval for its therapy, enhancing patient access in the United States. The company supports hospitals and wound clinics in implementing this therapy, aiming to improve patient outcomes and reduce healthcare costs associated with diabetic foot complications. Reapplix is actively expanding its presence in the US and European markets.

• Employees 37
• Founded 2008
• Annual Revenue $5400000
• Total Funding $25967181